Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 5/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 7/20 | 0.33 |
| ▸ | BAD | Q92934 | 7/20 | 0.33 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.32 |
| ▸ | DHODH | Q02127 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13865869 | 0.92 | ALDH1A1 (0.38) | NPC1PTGER4MAPT | |
| SCHEMBL13866073 | 0.90 | NPC1 (0.36) | NPC1PPARGALOX5APFEN1 | |
| SCHEMBL5667822 | 0.87 | NPC1 (0.36) | NPC1ALOX5APFEN1 | |
| SCHEMBL13865860 | 0.85 | NPC1 (0.37) | NPC1PPARGMCL1BAD | |
| SCHEMBL5668182 | 0.84 | NPC1 (0.43) | NPC1PPARGMAPT | |
| SCHEMBL13866137 | 0.82 | ALDH1A1 (0.36) | NPC1MAPT | |
| SCHEMBL13865949 | 0.82 | NPC1 (0.35) | NPC1MAPT | |
| SCHEMBL13871097 | 0.81 | NPC1 (0.38) | NPC1PPARGPTGER4 | |
| SCHEMBL13866098 | 0.81 | NPC1 (0.30) | NPC1 | |
| SCHEMBL13866135 | 0.79 | NPC1 (0.39) | NPC1PTGER4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137597-A1 | Novel quinoxalinone derivatives | MSD K.K. (JP) | 2009-05-28 | — | — | US | disclosed |
| US-7388010-B2 | Quinoxalinone derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-06-17 | — | — | US | disclosed |
| US-7148224-B2 | An enzyme inhibitors of cyclin-dependent kinases, antitumor agents; chemical intermediate synthesis | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-12-12 | — | — | US | disclosed |
| US-20050176719-A1 | Novel pyrazinone derivatives | MSD K.K. (JP) | 2005-08-11 | — | — | US | disclosed |
| US-6914062-B2 | Pyrazinone derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-07-05 | — | — | US | disclosed |
| EP-1295878-B1 | PYRAZINONE DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2004-09-15 | — | — | EP | disclosed |
| US-20030203907-A1 | An enzyme inhibitors of cyclin-dependent kinases, antitumor agents; chemical intermediate synthesis | MSD K.K. (JP) | 2003-10-30 | — | — | US | disclosed |
| EP-1295878-A1 | NOVEL PYRAZINONE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2003-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203907-A1 | An enzyme inhibitors of cyclin-dependent kinases, antitumor agents; chemical intermediate synthesis | CDK4, CDK6, CCNI | NPC1 4328/4885PPARG 1196/4885MCL1 1190/4885 |
| US-20090137597-A1 | Novel quinoxalinone derivatives | NDUFB1, NDUFB6, NDUFB7 | NPC1 1218/4885PPARG 2744/4885MCL1 1522/4885 |
| US-20050176719-A1 | Novel pyrazinone derivatives | CDK6, CDK4, CDK16 | NPC1 4126/4885PPARG 594/4885MCL1 1310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.